• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sexual Health Partnering Terms and Agreements Product Image

Sexual Health Partnering Terms and Agreements

  • Published: March 2014
  • Region: Global
  • 595 pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

The Sexual Health Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the sexual health partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter sexual health partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors sexual health technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual sexual health deals and contract documents as submitted READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in sexual health dealmaking

2.1. Introduction

2.2. Sexual health partnering over the years

2.3. Bigpharma sexual health dealmaking activity

2.4. Bigpharma not active in sexual health

2.5. Sexual health partnering by deal type

2.6. Sexual health partnering by industry sector

2.7. Sexual health partnering by stage of development

2.8. Sexual health partnering by technology type

2.9. Sexual health partnering by sexual health indication

2.10. Average deal terms for Sexual health

2.10.1 Sexual health headline values

2.10.2 Hematology upfront payments

2.10.3 Sexual health milestone payments

2.10.4 Sexual health royalty rates

Chapter 3 – Leading sexual health deals

3.1. Introduction

3.2. Top sexual health deals by value

3.3. Top sexual health deals involving bigpharma

Chapter 4 – Bigpharma sexual health deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma sexual health partnering company profiles

Abbott

Bayer

GlaxoSmithKline

Menarini

Merck & Co

Mylan

Pfizer

Roche

Teva

Valeant

Warner Chilcott

Watson

Chapter 5 – Sexual health partnering contracts directory

5.1. Introduction

5.2. By deal type

Asset purchase

Collaborative R&D

Development

Distribution

Joint venture

Licensing

Manufacturing

Marketing

Material transfer

Settlement

Sub-license

Termination

5.3. By stage of development

Formulation

Marketed

Phase II

Phase III

Preclinical

Regulatory

5.4. By technology type

Biological compounds

Devices

Diagnostics

Drug delivery

Small molecules

Chapter 6 – Sexual health dealmaking by indication

6.1. Introduction

6.2. Deals by therapeutic indication

Sexual Health

Bacterial vaginosis

Candida albicans (Thrush)

Contraception

Erectile dysfunction

Sexual dysfunction

Sexually transmitted disease (STI)

Chlamydia

Genital warts

Gonorrhea

Herpes

Syphilis

Trichomoniasis

Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 – Directory of sexual health deals by company A-Z 2009-2014

Appendix 2 – Directory of sexual health deals by deal type 2009-2014

Appendix 3 – Directory of sexual health deals by stage of development 2009-2014

Appendix 4 – Directory of sexual health deals by technology type 2009-2014

Appendix 5 – Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Reports

Order Form – Therapy Reports

Table of figures

Figure 1: Sexual health partnering since 2009

Figure 2: Bigpharma – top 50 – sexual health deals 2009 to 2012

Figure 3: Bigpharma sexual health deal frequency – 2009 to 2012

Figure 4: Inactive bigpharma in sexual health 2009-2014

Figure 5: Sexual health partnering by deal type since 2009

Figure 6: Sexual health partnering by industry sector since 2009

Figure 7: Sexual health partnering by stage of development since 2009

Figure 8: Sexual health partnering by technology type since 2009

Figure 9: Sexual health partnering by sexual health target since 2009

Figure 10: Sexual health deals with a headline value

Figure 11: Sexual health deal headline value distribution, US$million – discovery stage

Figure 12: Sexual health deal headline value distribution, US$million – preclinical stage

Figure 13: Sexual health deal headline value distribution, US$million – phase I stage

Figure 14: Sexual health deal headline value distribution, US$million – phase II stage

Figure 15: Sexual health deal headline value distribution, US$million – phase III stage

Figure 16: Sexual health deal headline value distribution, US$million – regulatory stage

Figure 17: Sexual health deal headline value distribution, US$million – marketed stage

Figure 18: Summary median headline value by stage of development, 2009-2014

Figure 19 Sexual Health deals with upfront payment values

Figure 20: Sexual health deal upfront payment distribution, US$million – discovery stage

Figure 21: Sexual health deal upfront payment distribution, US$million – preclinical stage

Figure 22: Sexual health deal upfront payment distribution, US$million – phase I stage

Figure 23: Sexual health deal upfront payment distribution, US$million – phase II stage

Figure 24: Sexual health deal upfront payment distribution, US$million – phase III stage

Figure 25: Sexual health deal upfront payment distribution, US$million – regulatory stage

Figure 26: Sexual health deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2009-2014

Figure 28: Sexual health deals with milestone payments

Figure 29: Sexual health deal milestone distribution, US$million – discovery stage

Figure 30: Sexual health deal milestone distribution, US$million – preclinical stage

Figure 31: Sexual health deal milestone distribution, US$million – phase I stage

Figure 32: Sexual health deal milestone distribution, US$million – phase II stage

Figure 33: Sexual health deal milestone distribution, US$million – phase III stage

Figure 34: Sexual health deal milestone distribution, US$million – regulatory stage

Figure 35: Sexual health deal milestone distribution, US$million – marketed stage

Figure 36: Sexual health deals with royalty rates, %

Figure 37: Sexual health deal royalty rate distribution, US$million – discovery stage

Figure 38: Sexual health deal royalty rate distribution, US$million – preclinical stage

Figure 39: Sexual health deal royalty rate distribution, US$million – phase I stage

Figure 40: Sexual health deal royalty rate distribution, US$million – phase II stage

Figure 41: Sexual health deal royalty rate distribution, US$million – phase III stage

Figure 42: Sexual health deal royalty rate distribution, US$million – regulatory stage

Figure 44: Summary median royalty rate by stage of development, 2009-2014

Figure 45: Top sexual health deals by value since 2009

Figure 46: Top sexual health deals signed by bigpharma value since 2009

Figure 47: Online partnering resources

Figure 48: Forthcoming partnering events
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in sexual health dealmaking

2.1. Introduction

2.2. Sexual health partnering over the years

2.3. Bigpharma sexual health dealmaking activity

2.4. Bigpharma not active in sexual health

2.5. Sexual health partnering by deal type

2.6. Sexual health partnering by industry sector

2.7. Sexual health partnering by stage of development

2.8. Sexual health partnering by technology type

2.9. Sexual health partnering by sexual health indication

2.10. Average deal terms for Sexual health

2.10.1 Sexual health headline values

2.10.2 Hematology upfront payments

2.10.3 Sexual health milestone payments

2.10.4 Sexual health royalty rates

Chapter 3 – Leading sexual health deals

3.1. Introduction

3.2. Top sexual health deals by value

3.3. Top sexual health deals involving bigpharma

Chapter 4 – Bigpharma sexual health deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma sexual health partnering company profiles

Abbott

Bayer

GlaxoSmithKline

Menarini

Merck & Co

Mylan

Pfizer

Roche

Teva

Valeant

Warner Chilcott

Watson

Chapter 5 – Sexual health partnering contracts directory

5.1. Introduction

5.2. By deal type

Asset purchase

Collaborative R&D

Development

Distribution

Joint venture

Licensing

Manufacturing

Marketing

Material transfer

Settlement

Sub-license

Termination

5.3. By stage of development

Formulation

Marketed

Phase II

Phase III

Preclinical

Regulatory

5.4. By technology type

Biological compounds

Devices

Diagnostics

Drug delivery

Small molecules

Chapter 6 – Sexual health dealmaking by indication

6.1. Introduction

6.2. Deals by therapeutic indication

Sexual Health

Bacterial vaginosis

Candida albicans (Thrush)

Contraception

Erectile dysfunction

Sexual dysfunction

Sexually transmitted disease (STI)

Chlamydia

Genital warts

Gonorrhea

Herpes

Syphilis

Trichomoniasis

Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 – Directory of sexual health deals by company A-Z 2009-2014

Appendix 2 – Directory of sexual health deals by deal type 2009-2014

Appendix 3 – Directory of sexual health deals by stage of development 2009-2014

Appendix 4 – Directory of sexual health deals by technology type 2009-2014

Appendix 5 – Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Reports

Order Form – Therapy Reports

Table of figures

Figure 1: Sexual health partnering since 2009

Figure 2: Bigpharma – top 50 – sexual health deals 2009 to 2012

Figure 3: Bigpharma sexual health deal frequency – 2009 to 2012

Figure 4: Inactive bigpharma in sexual health 2009-2014

Figure 5: Sexual health partnering by deal type since 2009

Figure 6: Sexual health partnering by industry sector since 2009

Figure 7: Sexual health partnering by stage of development since 2009

Figure 8: Sexual health partnering by technology type since 2009

Figure 9: Sexual health partnering by sexual health target since 2009

Figure 10: Sexual health deals with a headline value

Figure 11: Sexual health deal headline value distribution, US$million – discovery stage

Figure 12: Sexual health deal headline value distribution, US$million – preclinical stage

Figure 13: Sexual health deal headline value distribution, US$million – phase I stage

Figure 14: Sexual health deal headline value distribution, US$million – phase II stage

Figure 15: Sexual health deal headline value distribution, US$million – phase III stage

Figure 16: Sexual health deal headline value distribution, US$million – regulatory stage

Figure 17: Sexual health deal headline value distribution, US$million – marketed stage

Figure 18: Summary median headline value by stage of development, 2009-2014

Figure 19 Sexual Health deals with upfront payment values

Figure 20: Sexual health deal upfront payment distribution, US$million – discovery stage

Figure 21: Sexual health deal upfront payment distribution, US$million – preclinical stage

Figure 22: Sexual health deal upfront payment distribution, US$million – phase I stage

Figure 23: Sexual health deal upfront payment distribution, US$million – phase II stage

Figure 24: Sexual health deal upfront payment distribution, US$million – phase III stage

Figure 25: Sexual health deal upfront payment distribution, US$million – regulatory stage

Figure 26: Sexual health deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2009-2014

Figure 28: Sexual health deals with milestone payments

Figure 29: Sexual health deal milestone distribution, US$million – discovery stage

Figure 30: Sexual health deal milestone distribution, US$million – preclinical stage

Figure 31: Sexual health deal milestone distribution, US$million – phase I stage

Figure 32: Sexual health deal milestone distribution, US$million – phase II stage

Figure 33: Sexual health deal milestone distribution, US$million – phase III stage

Figure 34: Sexual health deal milestone distribution, US$million – regulatory stage

Figure 35: Sexual health deal milestone distribution, US$million – marketed stage

Figure 36: Sexual health deals with royalty rates, %

Figure 37: Sexual health deal royalty rate distribution, US$million – discovery stage

Figure 38: Sexual health deal royalty rate distribution, US$million – preclinical stage

Figure 39: Sexual health deal royalty rate distribution, US$million – phase I stage

Figure 40: Sexual health deal royalty rate distribution, US$million – phase II stage

Figure 41: Sexual health deal royalty rate distribution, US$million – phase III stage

Figure 42: Sexual health deal royalty rate distribution, US$million – regulatory stage

Figure 44: Summary median royalty rate by stage of development, 2009-2014

Figure 45: Top sexual health deals by value since 2009

Figure 46: Top sexual health deals signed by bigpharma value since 2009

Figure 47: Online partnering resources

Figure 48: Forthcoming partnering events

The Sexual Health Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the sexual health partnering deals and agreements entered into by the worlds leading healthcare companies

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos